Ala Abudayyeh

Ala Abudayyeh is an Associate Professor at The University of Texas MD Anderson Cancer Center, specializing in nephrology, oncology, and immunotherapy. Her research focuses on immune checkpoint inhibitor-related acute kidney injury, refractory immune-related adverse events, and onco-nephrology complications, including cisplatin-associated nephrotoxicity and high-dose methotrexate toxicity. Recent publications in JAMA Oncology, Blood, and Kidney International Reports highlight her work on magnesium supplementation, glucarpidase treatment, and SGLT2 inhibitors in cancer patients. She also investigates CAR T-cell therapy-associated renal pathology and image-guided renal biopsies in oncologic settings.